Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Next generation sequencing technologies (NGS) such as whole genome, whole exome, and large panels of genes, are rapidly changing the paradigm of medicine. Widespread use of NGS carries with it many ethical and practical challenges, some of which persist despite considerable debate. Whether laboratories and clinics should report variants of uncertain significance (VUS) to clinicians and/or patients, reinterpret VUS in response to the growing knowledge in the field, reissue reports to clinicians based on any revised classifications, and recontact patients, are all key unsolved issues in the clinical use of NGS. In addition, the question of whether, and to what extent, unsolicited findings (also known as incidental findings) should be returned to patients following NGS remains unanswered. In this presentation, Danya will discuss these issues, drawing on data from a systematic analysis 58 consent forms being used in the diagnostic setting to investigate their policies. 

If you would like to attend, please e-mail Jane Beinart at


Forthcoming events

Richard Doll Seminar -COVID-19: where to next?

Tuesday, 14 July 2020, 1pm to 2pm

WEH/Ethox Seminar: Consent and confidentiality in family medicine: reflections on the “ABC” case

Wednesday, 15 July 2020, 2.30pm to 4pm

This seminar will be held by Bluejeans videoconferencing, please email to register. A link to the meeting will then be sent to you on the day of the seminar.